B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

Axitinib

298 PubMed studies analyzed · 38 RCTs · Evidence Score: 51.2

Research Domains

Axitinib has been studied across 14 research domains including 🔬 Oncology, 🫘 Kidney, ❤️ Cardiovascular, 🛡️ Immunity, ⏳ Longevity & Aging. The primary research focus is 🔬 Oncology with 80% of studies addressing this area.

Loading evidence profile...

This evidence profile for Axitinib is generated deterministically from 298 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: v20260227-01. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.